<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: We studied the clinical effects of the <z:chebi fb="1" ids="35705">immunosuppressive agent</z:chebi> FK506 in patients with noninfectious <z:hpo ids='HP_0000554'>uveitis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: This study was designed as a multicenter open clinical trial in Japan </plain></SENT>
<SENT sid="2" pm="."><plain>Sixteen patients with noninfectious <z:hpo ids='HP_0000554'>uveitis</z:hpo> who had visited the <z:hpo ids='HP_0000554'>Uveitis</z:hpo> Survey Clinic of the Yokohama City University Hospital were given FK506 </plain></SENT>
<SENT sid="3" pm="."><plain>Eight had <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease; five, <z:e sem="disease" ids="C0042170" disease_type="Disease or Syndrome" abbrv="">Vogt-Koyanagi-Harada syndrome</z:e>; one, <z:e sem="disease" ids="C0029077" disease_type="Disease or Syndrome" abbrv="">sympathetic ophthalmia</z:e>; one, <z:chebi fb="46" ids="15035">retinal</z:chebi> <z:hpo ids='HP_0002633'>vasculitis</z:hpo>; and one, <z:e sem="disease" ids="C0036202" disease_type="Disease or Syndrome" abbrv="">sarcoidosis</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>In patients with <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease, ocular attack score before and after therapy was compared to judge clinical status </plain></SENT>
<SENT sid="5" pm="."><plain>For the other diseases, the ocular inflammatory symptoms were observed after the initiation of FK506 treatment </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients underwent blood and urine examinations, electrocardiography, and chest x-rays before and after FK506 treatment </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Of the patients with <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease, five improved, one remained unchanged, one deteriorated, and the status of one could not be determined </plain></SENT>
<SENT sid="8" pm="."><plain>Of the patients with <z:e sem="disease" ids="C0042170" disease_type="Disease or Syndrome" abbrv="">Vogt-Koyanagi-Harada syndrome</z:e>, four improved, and one remained unchanged </plain></SENT>
<SENT sid="9" pm="."><plain>The patient with <z:e sem="disease" ids="C0029077" disease_type="Disease or Syndrome" abbrv="">sympathetic ophthalmia</z:e> improved, the patient with <z:chebi fb="46" ids="15035">retinal</z:chebi> <z:hpo ids='HP_0002633'>vasculitis</z:hpo> remained unchanged, and the status of the patient with <z:e sem="disease" ids="C0036202" disease_type="Disease or Syndrome" abbrv="">sarcoidosis</z:e> could not be determined </plain></SENT>
<SENT sid="10" pm="."><plain>Major adverse effects were sensations of warmth, <z:hpo ids='HP_0002917'>hypomagnesemia</z:hpo>, <z:hpo ids='HP_0000082'>renal dysfunction</z:hpo>, <z:hpo ids='HP_0000833'>glucose intolerance</z:hpo>, <z:hpo ids='HP_0002018'>nausea</z:hpo>, <z:hpo ids='HP_0002013'>vomiting</z:hpo>, and disorders of the central <z:mp ids='MP_0008912'>nervous</z:mp> system </plain></SENT>
<SENT sid="11" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> adverse effects disappeared or improved when FK506 was stopped or when the dosage was decreased </plain></SENT>
<SENT sid="12" pm="."><plain><z:hpo ids='HP_0000082'>Renal dysfunction</z:hpo> and <z:hpo ids='HP_0000833'>glucose intolerance</z:hpo> appeared when the blood level of FK506 was high </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: FK506 was effective in patients with <z:hpo ids='HP_0000554'>uveitis</z:hpo>, but it is important to monitor the occurrence of adverse effects </plain></SENT>
</text></document>